Flowable Hemostats Market Study Highlights How Industry Demand Is Evolving

The flowable hemostats market is on track for significant expansion as medical advancements continue to drive demand. This sector is becoming increasingly important in surgical and trauma care settings, where rapid and reliable bleeding control is critical. Let's delve into the current market size, standout companies, key trends, and the segments shaping this industry's future.

Projected Growth Trajectory of the Flowable Hemostats Market
The market for flowable hemostats is forecasted to grow impressively, reaching a valuation of $1.47 billion by 2030. This growth represents a compound annual growth rate (CAGR) of 7.5%. Several factors are contributing to this upward trend, including the urgent need for faster bleeding control methods, heightened attention to patient safety, the rise of minimally invasive and robotic surgeries, advancements in bioresorbable material technologies, and increased use in emergency and trauma care. The forecast period will also see trends such as broader adoption of flowable hemostats during complex surgical procedures, a surge in combination hemostatic products, demand for rapid hemostasis solutions, and a push toward biocompatible materials in surgical applications.

The flowable hemostats market size has grown strongly in recent years. It will grow from $1.02 billion in 2025 to $1.1 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to growth in surgical procedure volumes, increasing adoption of advanced surgical tools, availability of gelatin-based hemostatic agents, expansion of specialty surgical disciplines, improved surgeon awareness of flowable hemostats.

Download a free sample of the flowable hemostats market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20552&type=smp&utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Key Drivers Supporting the Flowable Hemostats Market Growth
One primary factor fueling growth is the emphasis on achieving quick and effective bleeding control during surgeries, which helps reduce complications and improve recovery outcomes. Additionally, the expansion of minimally invasive surgical techniques-including robotic-assisted operations-is boosting the demand for advanced hemostatic agents tailored to these procedures.

Another important influence is the growing focus on patient safety, encouraging healthcare providers to opt for biocompatible and efficient products that minimize risks. Innovations in bioresorbable materials further enhance the performance and acceptance of these hemostatic solutions in clinical settings. Moreover, the increasing frequency of trauma and emergency surgeries worldwide contributes to the rising need for reliable flowable hemostats.

View the full flowable hemostats market report:
https://www.thebusinessresearchcompany.com/report/flowable-hemostats-global-market-report?utm_source=Open&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Making an Impact in the Flowable Hemostats Industry
This market features a competitive landscape with several major players, such as Pfizer Inc., Johnson & Johnson Services Inc., Medtronic plc, Medline Industries Inc., Stryker Corporation, Baxter International Inc., B Braun Melsungen AG, Becton dic*kinson and Company, Cook Medical Inc., Teleflex Incorporated, Mallinckrodt Pharmaceuticals, Integra LifeSciences Holdings Corporation, Gelita Medical GmbH, Ferrosan Medical Devices A/S, Marine Polymer Technologies Inc., Axio Biosolutions Private Limited, Hemostasis LLC, Aegis Lifesciences Private Limited, Medcura Health Inc., Arch Therapeutics Inc., and Starch Medical Inc.

A notable transaction in this space occurred in May 2025, when Merit Medical Systems Inc., a US-based manufacturer specializing in interventional and therapeutic medical devices, acquired Biolife Delaware LLC for around $120 million. This acquisition granted Merit access to Biolife's proprietary hemostatic product range, including StatSeal and WoundSeal, enhancing Merit's portfolio with reliable bleeding control solutions designed for vascular access and post-procedure care. Biolife Delaware is recognized for developing hemostatic products in powder and disc formats that rapidly seal bleeding at catheter and procedural access points.

Emerging Trends Opening New Avenues in Flowable Hemostats
Industry leaders are increasingly focused on innovating with surgically advanced hemostatic agents tailored to the nuances of modern procedures. One such breakthrough is "no-swell" technology, which ensures that the hemostatic agent does not absorb fluids and expand, a critical feature for surgeries where swelling could lead to complications.

For example, Medcura Inc., a US surgical technology company, received FDA breakthrough device designation in January 2023 for its LifeGel flowable technology. LifeGel offers a unique solution by controlling bleeding in surgeries where swelling is a concern. Unlike traditional hemostatic agents, LifeGel is fully hydrated and ready to use without swelling, reducing risks such as nerve damage and paralysis. It is cost-effective, has antimicrobial properties, is relatively transparent, and adheres to tissues, making it a safer and more efficient choice for managing bleeding during complex surgeries.

Breakdown of Major Segments in the Flowable Hemostats Market
The flowable hemostats market is categorized into several key segments for better understanding:
1) By Product: Active Hemostats, Passive Hemostats, Combination Hemostats
2) By Material: Porcine Gelatin, Bovine Gelatin
3) By Application: General Surgery, Cardiac Surgery, Vascular Surgery, Neuro and Spine Surgery, Orthopedic Surgery, Other Applications
4) By End User: Hospitals and Clinics, Ambulatory Surgery Centers

Within these broad segments, there are further subcategories, such as:
- Active Hemostats include fibrin sealants, thrombin-based hemostats, collagen-based hemostats, and biodegradable polymer hemostats.
- Passive Hemostats are comprised of gauze-based hemostats, sponges and pads, cellulose-based hemostats, and granule-based hemostats.
- Combination Hemostats cover fibrinogen and thrombin combination products, collagen and fibrin combination products, synthetic combination hemostats, and bioresorbable combination hemostats.

This detailed segmentation allows for a comprehensive view of the flowable hemostats market and highlights the diversity of products catering to various surgical needs.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.